Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–479 of 479 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botulinum Toxin Type A - OnabotulinumtoxinA Clear all
Terminated Phase 4 Interventional

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease

NCT00477802
View directory record Official record
Conditions
Parkinson Disease
Interventions
Botulinum Toxin Type A, Placebo
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2009 · Synced Oct 15, 2026, 9:28 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

NCT05766683
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 9:28 AM EDT
Terminated Not applicable Interventional

Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy

NCT00250081
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Tendon transfer, Botulinum Toxin injections in Upper Extremity, Regularly ongoing therapy
Procedure
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Sacramento, California • Wilmington, Delaware • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05146999
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
QM1114-DP, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Homewood, Alabama • Manhattan Beach, California • Vista, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 15, 2026, 9:28 AM EDT
Terminated Phase 1 Interventional

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

NCT03069911
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
OnabotulinumtoxinA, Control
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

NCT04124939
View directory record Official record
Conditions
Overactive Bladder
Interventions
OnabotulinumtoxinA 100 Units
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Greensboro, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study

NCT01529788
View directory record Official record
Conditions
Intrinsic Aging of Skin, Solar Elastosis
Interventions
Right lateral orbital injection of Botox Cosmetic or Dysport, Left lateral orbital injection of Botox Cosmetic or Dysport
Drug
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

NCT02261493
View directory record Official record
Conditions
Facial Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

NCT05216263
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

NCT02718118
View directory record Official record
Conditions
Glabellar Lines, Wrinkles
Interventions
Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Greenwood Village, Colorado • Coral Gables, Florida • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

NCT02191579
View directory record Official record
Conditions
Migraine Disorders
Interventions
onabotulinumtoxinA, Topiramate
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Encinitas, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 15, 2026, 9:28 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 3 Interventional Results available

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT02610868
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
Other · Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

NCT00856414
View directory record Official record
Conditions
Skin Aging
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 15, 2026, 9:28 AM EDT
Terminated Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT02973269
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
daxibotulinumtoxin type A, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

NCT02498769
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Joseph Mathew, M.D.
Other
Eligibility
50 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

NCT05089851
View directory record Official record
Conditions
Wrinkles, Photoaging, Fine Lines
Interventions
Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Combination Product
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 15, 2026, 9:28 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Randomization of Botox for Stent Pain and Irritative Voiding Symptoms

NCT02078895
View directory record Official record
Conditions
Lower Urinary Tract Discomfort, Stent Pain
Interventions
Botox
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 15, 2026, 9:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects

NCT03991299
View directory record Official record
Conditions
Obese, Diabetes Mellitus, Type 2
Interventions
Botox 200 UNT Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 15, 2026, 9:28 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder

NCT01350375
View directory record Official record
Conditions
Forward Head Posture With Associated Episodic Headache Disorder
Interventions
Botox, Saline
Drug
Lead sponsor
The Research Center of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 15, 2026, 9:28 AM EDT